CD56
Allo-HSCT
CD56bright NK
DNAM-1
EBV reactivation
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
23
01
2024
accepted:
31
05
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
11
6
2024
Statut:
aheadofprint
Résumé
Natural killer (NK) cells are equipped with anti-Epstein-Barr virus (EBV) function, however, whether EBV infection will affect NK cells reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. To identify the characteristics of NK cells, we prospectively enrolled 11 patients who occurred EBV reactivation post allo-HSCT and 11 patients without EBV infection as control. We found that that EBV infection induced the expansion of CD56
Identifiants
pubmed: 38862793
doi: 10.1007/s00277-024-05827-4
pii: 10.1007/s00277-024-05827-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : National Natural Science Foundation of China
ID : 82270228
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Science, Technology& Innovation Project of Xiongan New area
ID : 2023XACX0004
Organisme : Peking University People's Hospital Research and Development Funds
ID : RDL2021-01
Organisme : Peking University People's Hospital Research and Development Funds
ID : RDL2021-01
Organisme : Peking University People's Hospital Research and Development Funds
ID : RDL2021-01
Organisme : Peking University People's Hospital Research and Development Funds
ID : RDL2021-01
Organisme : Peking University People's Hospital Research and Development Funds
ID : RDL2021-01
Organisme : National Key Research and Development Program of China
ID : 2022YFA1103304
Organisme : National Key Research and Development Program of China
ID : 2022YFA1103304
Organisme : National Key Research and Development Program of China
ID : 2022YFA1103304
Organisme : National Key Research and Development Program of China
ID : 2022YFA1103304
Organisme : National Key Research and Development Program of China
ID : 2022YFA1103304
Organisme : National Key Research and Development Program of China
ID : 2022YFA1103304
Organisme : Beijing Nova Program
ID : 20220484235
Organisme : Beijing Nova Program
ID : 20220484235
Organisme : Beijing Nova Program
ID : 20220484235
Organisme : Beijing Nova Program
ID : 20220484235
Organisme : Beijing Nova Program
ID : 20220484235
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Prockop S et al (2020) Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest 130(2):733–747
doi: 10.1172/JCI121127
pubmed: 31689242
pmcid: 6994129
Pappworth IY, Wang EC, Rowe M (2007) The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 81(2):474–482
doi: 10.1128/JVI.01777-06
pubmed: 17079298
Williams LR et al (2016) Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle. J Virol 90(2):947–958
doi: 10.1128/JVI.01932-15
pubmed: 26537677
Williams H et al (2005) The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol 129(2):266–274
doi: 10.1111/j.1365-2141.2005.05452.x
pubmed: 15813855
Azzi T et al (2014) Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124(16):2533–2543
doi: 10.1182/blood-2014-01-553024
pubmed: 25205117
pmcid: 4199955
Wiesmayr S et al (2012) Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol 42(2):541–550
doi: 10.1002/eji.201141832
pubmed: 22105417
Vietzen H et al (2023) HLA-E-restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD. Blood 141(13):1560–1573
doi: 10.1182/blood.2022017650
pubmed: 36477802
Hsieh WC et al (2021) NK cell receptor and ligand composition influences the clearance of SARS-CoV-2. J Clin Invest 131(21):e146408
Manser AR, Uhrberg M (2016) Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance. Cancer Immunol Immunother 65(4):417–426
doi: 10.1007/s00262-015-1750-0
pubmed: 26288343
Lutz CT et al (2011) Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults. J Immunol 186(8):4590–4598
doi: 10.4049/jimmunol.1002732
pubmed: 21402893
Gayoso I et al (2011) Immunosenescence of Human Natural Killer Cells. J Innate Immun 3(4):337–343
doi: 10.1159/000328005
pubmed: 21576928
Xu W et al (2020) The untwining of immunosenescence and aging. Semin Immunopathol 42(5):559–572
doi: 10.1007/s00281-020-00824-x
pubmed: 33165716
pmcid: 7665974
Phan MT et al (2017) Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity. Hum Immunol 78(2):103–112
doi: 10.1016/j.humimm.2016.11.006
pubmed: 27884732
Styczynski J et al (2009) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43(10):757–70
doi: 10.1038/bmt.2008.386
pubmed: 19043458
Zhao XY et al (2020) Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur J Immunol 50(9):1374–1385
doi: 10.1002/eji.201948375
pubmed: 32357256